Brief: Regulus Therapeutics Reports Sanofi Notified Co Of Its Decision To Terminate Study Of Lademirsen

Regulus Therapeutics

15/07/2022 21:11

July 15 (Reuters) - Regulus Therapeutics Inc  RGLS.O :
    * REGULUS THERAPEUTICS- ON JULY 12, SANOFI NOTIFIED CO OF
ITS
DECISION TO TERMINATE PHASE 2 CLINICAL STUDY OF LADEMIRSEN
(RG-012) FOR  TREATMENT OF ALPORT SYNDROME
    * REGULUS THERAPEUTICS INC- SANOFI TERMINATED HERA STUDY FOR
FAILURE TO MEET SANOFI’S PRE-DEFINED FUTILITY CRITERIA
    * REGULUS THERAPEUTICS INC- SANOFI ALSO NOTIFIED THE COMPANY
THAT
IT IS CURRENTLY EVALUATING DIFFERENT OPPORTUNITIES WITH RESPECT
TO RG-012

Source text: (https://bit.ly/3IIpb5c)
Further company coverage:  RGLS.O 

 ((Reuters.Briefs@thomsonreuters.com;))